Literature DB >> 467897

Effect of uracil on metabolism of 5-fluorouracil in vitro.

K Ikenaka, T Shirasaka, S Kitano, S Fujii.   

Abstract

The effect of uracil on the metabolism of 5-fluorouracil (5-FU) in vitro was studied. 5-FU was mainly phosphorylated in intact Yoshida sarcoma cells, whereas it was mainly degraded in liver slices. Uracil inhibited degradation of 5-FU much more than its phosphorylation; incubation of 2,500 microM of uracil with 2.5 microM of 5-FU (molar ratio, 1,000:1) inhibited the degradation of 5-FU by 70%, but did not affect its phosphorylation. With homogenates of Yoshida sarcoma or liver uracil inhibited degradation of 5-FU greatly, phosphorylation of 5-FU by alpha-D-ribose 1-phosphate (RiblP) and ATP to some extent, and phosphorylation by 5-phospho-alpha-D-ribosyl diphosphate (PPRibP) very little. The activities of the enzymes involved in the metabolism of 5-FU in various tissues were also determined. Degradation of 5-FU was much faster in liver than in other tissues and was very slow in tumor tissue. Phosphorylation of 5-FU with RiblP and ATP was rapid in Yoshida sarcoma and bone marrow. Phosphoribosyltransferase activity was high in Yoshida sarcoma and thymus, but low in bone marrow.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 467897

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  33 in total

1.  Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.

Authors:  R Pazdur; Y Lassere; E Diaz-Canton; B Bready; D H Ho
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  Oral tegafur/uracil.

Authors:  K Wellington; K L Goa
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  A Physiologically Based Pharmacokinetic-Pharmacodynamic Model for Capecitabine in Colorectal Cancer Rats: Simulation of Antitumor Efficacy at Various Administration Schedules.

Authors:  Shuhei Sakai; Shinji Kobuchi; Yukako Ito; Toshiyuki Sakaeda
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-02-19       Impact factor: 2.441

4.  Relationships between body composition parameters and fluorouracil pharmacokinetics.

Authors:  Milena Gusella; Sivia Toso; Eros Ferrazzi; Mariano Ferrari; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 5.  UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.

Authors:  Fumihiro Tanaka
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

6.  Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.

Authors:  Masanori Terashima; Hisataka Fujiwara; Akinori Takagane; Kaoru Abe; Takashi Irinoda; Tsutomu Nakaya; Hitoshi Yonezawa; Kenichi Oyama; Kazuyoshi Saito; Norio Kanzaki; Satoshi Ohtani; Tsuyoshi Nemoto; Yutaka Hoshino; Michihiko Kogure; Mitsukazu Gotoh
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

7.  Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.

Authors:  Y Sawai; K Yamaoka; T Nakagawa
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

8.  Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia.

Authors:  M Iigo; A Hoshi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  Interactions between UFT and anticoagulants in lung cancer patients.

Authors:  J Ogawa; H Inoue; T Tsurumi; H Inoue; S Koide; S Kawada; A Shohtsu
Journal:  Jpn J Surg       Date:  1988-05

10.  Report on nationwide pooled data and cohort investigation in UFT phase II study.

Authors:  K Ota; T Taguchi; K Kimura
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.